drugset / Trial / NCT03246399

A Study of the Safety, Tolerability, and Pharmacokinetics of SM04690 Injectable Suspension Following Single Intradiscal Injection in Subjects With Degenerative Disc Disease

NCT03246399 ↗

Phase 1 Terminated 6 enrolled Biosplice Therapeutics, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

SM04690-DDD-01 is a Phase 1, open-label, dose escalation study. SM04690 Injectable Suspension will be administered via a single intradiscal injection to subjects with degenerative disc disease (DDD) under fluoroscopic guidance. Groups of 6 subjects will be enrolled in successive cohorts. Subjects will participate in a 6 month follow-up period. Clinic visits will be Screening, Treatment Visit Day 1, and Follow-up Visit Days 2, 15, 28, 60, 90, 135, and 180.

Timeline

Start
2017-07-26
Primary completion
2018-11-14
Completion
2018-12-04

Outcome

Outcome not reported

Stopped (Enrollment): “Study stopped due to business reasons, following full enrollment of the first dose cohort.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Lorecivivint Small molecule 0.03 mg Other
Subject Lorecivivint Small molecule 0.07 mg Other
Subject Lorecivivint Small molecule 0.15 mg Other